NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke,
NovaGo Therapeutics has raised €35M across 2 funding rounds from 7 investors, most recently a Series B round in Sep 2026. Based in Schlieren, Switzerland; active in Healthtech. Data as of 21 Sept 2026.
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2026-09-02 | Series B | €26M | Existing investors,Neurimmune Holding,new investors,Pureos Ventures,Swiss Paraplegic Foundation,Wings for Life | View deal → |
| 2019-01-01 | Series A | €8.9M | Neurimmune Holding,Pureos Bioventures | View deal → |
